---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-23-000004"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T20:05:18.470586+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Labcorp appoints Thomas Pike to lead Drug Development unit; will become CEO of spin-off company

## Summary
- Thomas Pike appointed President and CEO of Drug Development Clinical Development business, effective Jan 9, 2023.
- Upon planned spin-off (expected mid-2023), Pike will become CEO and Chairman of the independent publicly listed company.
- Paul Kirchgraber, current EVP and CEO of Drug Development, will depart after the spin-off; he continues leading Early Development, Central Laboratories, and Global Oncology.
- Labcorp to announce the new company's Board of Directors, including lead independent director, in coming months.

## SEC filing metadata
- accession: 0000920148-23-000004
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/lh-20230104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-23-000004
- JSON: https://secwatch.observer/filing/0000920148-23-000004.json
- Plain text: https://secwatch.observer/filing/0000920148-23-000004.txt

## Key facts
- Executive change
  Thomas Pike was appointed as President and Chief Executive Officer of Drug Development Clinical Development business unit at LABCORP HOLDINGS INC..
  - Action: appointed
  - Role: President and Chief Executive Officer of Drug Development Clinical Development business unit
  source text: Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm
- Executive change
  Paul Kirchgraber departed as EVP and CEO of Drug Development business segment at LABCORP HOLDINGS INC..
  - Action: intends to depart
  - Role: EVP and CEO of Drug Development business segment
  source text: Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.